In addition, talquetamab mediated potent killing of MM cells derived from patients with newly diagnosed MM or R/R MM, which was accompanied by a significant increase in CD4+ and CD8+ T cell activation and degranulation [20]. This evidence concerns the gene CD4 and Miyoshi myopathy.